JURY RULES UNANIMOUSLY IN PFIZER'S FAVOR IN AMLODIPINE PATENT CASE

Pfizer Inc said that a federal court jury in the Eastern District of Virginia (Alexandria) has ruled unanimously that Pfizer does not infringe Synthon IP's U.S. patent covering a process for making amlodipine, the active ingredient in Norvasc. Norvasc is the world's most-prescribed branded medicine for treating hypertension.

Genetic Engineering News (http://www.genengnews.com/news/bnitem.aspx?name=4817594)